Jump to content

1-Formyl-LSD

From Wikipedia, the free encyclopedia

1-Formyl-LSD
Clinical data
Other names1-Formyl-LSD; 1-Formyl-N,N-diethyllysergamide; N,N-Diethyl-1-formyl-6-methyl-9,10-didehydroergoline-8β-carboxamide; 1F-LSD
Routes of
administration
Oral; Sublingual
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • N,N-Diethyl-1-formyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
Chemical and physical data
FormulaC21H25N3O2
Molar mass351.450 g·mol−1
3D model (JSmol)
  • CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C=O)CC
  • InChI=1S/C21H25N3O2/c1-4-23(5-2)21(26)15-9-17-16-7-6-8-18-20(16)14(12-24(18)13-25)10-19(17)22(3)11-15/h6-9,12-13,15,19H,4-5,10-11H2,1-3H3/t15-,19-/m1/s1
  • Key:SSEPNHFOVYUBHO-DNVCBOLYSA-N

1-Formyl-LSD, also known as 1-formyl-N,N-diethyllysergamide and sometimes referred to as 1F-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is the 1-formyl derivative of LSD.[1][2][3]

The drug is assumed to act as a prodrug of LSD.[1] It produces psychedelic effects in humans similarly to LSD.[2] Effective doses have been reported to be 100 to 150 μg orally or sublingually.[2] Very little is known about the pharmacology and properties of 1-formyl-LSD.[1]

1-Formyl-LSD was first described in the scientific literature by 2021.[2] It first emerged as a novel designer drug online in January 2019.[1][2]

Another drug, 1‐(furan‐2‐carbonyl)‐LSD (SYN-L-005), has also been referred to as "1F-LSD".[3]

Interactions

[edit]

See also

[edit]

References

[edit]
  1. ^ a b c d e "1F-LSD". АИПСИН (in Russian). Retrieved 26 July 2025.
  2. ^ a b c d e f Catalani V, Arillotta D, Corkery JM, Guirguis A, Vento A, Schifano F (9 February 2021). "Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach". Frontiers in Psychiatry. 11 632405. doi:10.3389/fpsyt.2020.632405. ISSN 1664-0640. PMC 7900492. PMID 33633599.
  3. ^ a b Brandt SD, Kavanagh PV, Gare S, Elliott SP, Stratford A, Halberstadt AL (3 December 2024). "Analytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD)". Drug Testing and Analysis. 17 (8): 1283–1293. doi:10.1002/dta.3829. ISSN 1942-7603. PMC 12319525. PMID 39624022.
[edit]